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Abstract
Introduction: Alkaptonuria (also known as ochronosis) is a genetic disorder characterised by the
accumulation of homogentisic acid deposits in connective tissue. In rare cases, ochronosis can
cause valvular heart disease.
Case presentation: We present the case of a 68-year-old Caucasian man with alkaptonuria-
associated degenerative valvular defects with aortic, mitral and tricuspid valve insufficiency. The
patient did not have any cardiac complaints and was referred to our clinic for evaluation of a
conspicuous new heart murmur.
Conclusion: This case report shows that early diagnosis of cardiovascular ochronosis gives us the
opportunity to use conservative treatment to slow down the progression of valvular dysfunction.
Introduction
Alkaptonuria is a rare autosomal-recessive metabolic dis-
order characterised by the deficiency of homogentisic 1,2-
dioxygenase (HGO) [1]. Due to the lack of this enzyme,
homogentisic acid cannot be metabolised and is depos-
ited within various tissues of the body as a polymerised
product. The common clinical manifestations of alkap-
tonuria are (i) homogentisic aciduria, (ii) ochronosis
(deposition of bluish-black pigment in all connective tis-
sues), and (iii) arthritis. While alkaptonuria itself is
asymptomatic, ochronosis usually develops in the fourth
decade of life. There is no cure for alkaptonuric ochrono-
sis and the aim of treatment is to prevent complications.
Case presentation
A 68-year-old Caucasian man was referred to our cardiol-
ogy clinic in February 2008 for further evaluation of a con-
spicuous new heart murmur. The patient did not have any
cardiac complaints and did not suffer from angina pec-
toris or dyspnoea. The patient had advanced gonarthrosis
of the left knee, advanced degeneration of the cervical
spine and advanced bilateral omarthrosis. His medical
history included kidney stone surgery (1988), diagnosis
of ochronosis based on a biopsy of the knee joint (1995),
total hip replacement (1997), Miller-Galante II prosthesis
of the right knee (1997), periosteal rupture of the left
Achilles tendon with transosseous re-fixation (1999), ven-
tral corporectomy at C4 and discectomy at C3/C4 and C4/
C5 after cervical spinal canal stenosis with myelopathy at
C3-C5, and ventral and dorsal osteochondrosis (2001).
Family history revealed that his brother also had ochron-
osis. The patient was not on any medication.
On physical examination, the patient was found to be in
a moderately reduced general condition and in a regular
nutritional status. His body mass index was 25.8 kg/m2.
He had a blood pressure of 130/80 mmHg bilaterally and
a pulse rate of 80 beats/min. Dyspnoea, cyanosis and liver
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skin spots were not observed. Bluish-black pigmentations
were found on several parts of the sclera (Figure 1). The
patient's pupils were of average width and showed
prompt response to light. No arcus lipoides, no goitre and
no superior vena cava syndrome were noticed. His thorax
and chest expansion were symmetrical. Breath sounds
were vesicular and percussion resonant, with no crepita-
tions or evidence of a pleural effusion. His heart beat was
regular with a grade 2/6 diastolic murmur at the apex and
a grade 2/6 systolic murmur over the mitral and tricuspid
valves. His abdomen was soft and non-tender to palpa-
tion, liver and spleen were not enlarged, and there was no
costo-vertebral-angular tenderness. Unilateral oedema on
the left ankle was observed. Also, the left foot pulse was
absent, while normal central and peripheral pulses were
symmetrically palpable.
Results of the patient's laboratory examination showed
252 mg/dl total cholesterol, 84 mg/dl triglycerides, 66
mg/dl high-density lipoprotein and 72 mg/dl low-density
lipoprotein. Inflammatory markers were not elevated and
anti-streptolysin O (ASO) titre was not raised. The
patient's urine turned brownish black when left standing
for some time.
An electrocardiogram (ECG) test showed a sinus rhythm
of 72 beats/min with left axis deviation (-57 degrees). The
patient's depolarisation and repolarisation phases were
normal. During an exercise ECG using a treadmill set up
to 125 watts workload, his blood pressure increased from
160/90 mmHg to 160/100 mmHg and his pulse rate from
68 to 158 beats/min. When the exercise ECG was stopped
at the point of exhaustion, no angina pectoris, dyspnoea,
significant ST segment depression or profound dysrhyth-
mia were observed. His blood pressure and pulse rate nor-
malised within 3 minutes of recovery.
An echocardiogram revealed that the patient's left atrium
was normal in size while his left ventricle was slightly
dilated (Figure 2). The pumping function of the left heart
was normal - there was no evidence of hypertrophy - and
the aortic valve had three cusps. A Doppler echocardio-
gram showed a minor to moderate aortic insufficiency, a
combined mitral valve defect with an opening size of 1.6
cm2 with mild to moderate regurgitation, and a mild tri-
cuspid regurgitation. No pericardial effusion was
detected. The patient's right heart was normal in size with-
out any signs of stasis.
A histopathological analysis of the patient revealed
brownish deposits between the collagen fibre bundles of
a knee joint biopsy sample. The pigment was found both
extracellularly and intracellularly. The appearance of the
pigment was variable, being coarse, like haemosiderin
and fine, like granules. Iron staining was negative and no
inflammatory or post-inflammatory changes were
observed. Taken together, the patient's histopathology
was characteristic for ochronosis.
Based on cardiac investigations, an alkaptonuria-associ-
ated degenerative valve defect with aortic, mitral and tri-
cuspid valve insufficiency was diagnosed. The decision for
using conservative therapy was reached and the patient
was treated with an angiotensin-converting enzyme
(ACE) inhibitor (2.5 mg/day ramipril).
At follow-up examinations in April and November 2008,
the patient presented in a stable condition. However, in
February 2009, the patient was hospitalised because of
cardiac decompensation.
Discussion
Alkaptonuria occurs with a very low prevalence rate of one
in 100,000 to 250,000 in most countries with the notable
exception in Slovakia, where the disease appears in 1 in
19,000 people [2]. The disease was even detected in an
Egyptian mummy [3] and from mediaeval times there are
descriptions of the disease which were, however, misinter-
preted at that time. In 1866, Rudolph Virchow published
the first original description of the disease [4].
Alkaptonuria is an autosomal-recessive inherited genetic
disorder of the tyrosine metabolism. Considering con-
served synteny, the HGO gene could be mapped to chro-
mosome 3q in six alkaptonuria pedigrees of Slovak origin
[5]. So far, 67 different mutations in the HGO gene have
been identified [6]. The deficiency of HGO results in the
accumulation of homogentisic acid followed by an
increased excretion of the metabolite [1]. At first, the urine
has a normal colour but after a couple of hours it turns
dark due to the high level of homogentisic acid. The
ochronotic pigment results from oxidative polymerisation
of homogentisic acid [7]. We did not perform a biochem-
ical analysis to determine whether the level of homogenti-
sic acid was elevated but diagnosed the disease based on
histopathological and clinical examinations.
Ochronotic pigment on the sclera of the eyes of the patient Figure 1
Ochronotic pigment on the sclera of the eyes of the 
patient.
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In 20% of cases, alkaptonuria is diagnosed before one
year of age, while in 80% the mean age at the time of diag-
nosis is 29 [6]. In general, the severity of the disease
progresses after the age of 30 and more rapidly in men
than in women [6]. The diagnosis of alkaptonuria is usu-
ally based on the detection of degenerative joint disease,
ochronosis of the connective tissue and the darkening of
urine after alkalinisation. In addition, alkaptonuria may
be associated with nephrolithiasis, which develops at a
mean age of 64 [6] and could be the leading symptom.
Clinical findings include the pigmentation of the ear car-
tilage and the sclera of the eyes, which only occur after the
age of 30 and are very variable in appearance [6,8]. Almost
all patients suffer from arthritis of the knee and hip and,
occasionally, of the shoulder. By the age of 55 years, 50%
of patients with alkaptonuria have undergone at least one
joint replacement [6]. However, alkaptonuria-associated
arthritis is clinically and radiologically similar to osteoar-
thritis for which it can be mistaken [9]. Arthritis in
patients with alkaptonuria is caused by chemical irritation
of deposited homogentisic acid, an altered metabolism of
chondrocytes and an altered cross linkage of collagen
[10]. Our patient showed most of the histopathological
and clinical symptoms, and the final diagnosis was made
on the basis of a biopsy taken from his knee joint.
Alkaptonuria is occasionally associated with aortic steno-
sis but generalised arteriosclerosis and calcification of the
heart valves have also been described [11-15]. Cardiovas-
cular ochronosis is usually a benign disease. The disposi-
tion of ochronotic pigment serves as a trigger for the
dystrophic calcification of valves. Generally, the pigment
is deposited at the edge and annulus of valves and may
lead to degeneration of cells [11]. However, in our
patient's case the histological analysis of valvular material
was not possible as there was no indication for valve
replacement. Other conditions that could have caused val-
vular heart disease in our patient are rheumatic fever,
endocarditis, age-related calcification of the valves, car-
diac dilation and congenital malformations. In patients
diagnosed with alkaptonuria, the aortic valve is most fre-
quently affected, followed by the mitral and pulmonary
valves. It is also possible that more than one valve is
affected. As in our patient's case, aortic and mitral valve
regurgitation have been previously observed [12,13].
Alkaptonuria-associated valvular heart disease usually
Echocardiogram of the patient Figure 2
Echocardiogram of the patient. (A) Apical four-chamber view with aorta. (B) Parasternal long axis view with the root of 
the aorta, left atrium and left ventricular outflow tract. Both images show moderate calcification of the aortic valve and slight 
calcification at the anterior leaflet of the mitral valve. (C) Apical two-chamber view with aorta. Colour flow mode indicates 
moderate aortic regurgitation. (D) Apical four-chamber view. Colour flow mode indicates mild mitral regurgitation.Journal of Medical Case Reports 2009, 3:9302 http://www.jmedicalcasereports.com/content/3/1/9302
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becomes clinically apparent in middle-aged patients
(mean age 54 years [6]). Thus, our patient, at 68 years old,
was somewhat older for an initial diagnosis of cardiac
ochronosis.
Although there is no effective treatment for alkaptonuria
[16], the prognosis is relatively good. Large doses of vita-
min C (1 g) have been used to prevent the deposition of
ochronotic pigment [17]. Nitisinonen is an inhibitor of 4-
hydroxyphenylpyruvate dioxygenase, the enzyme that
produces homogentisic acid. Nitisinonen has been shown
to reduce drastically the production and urinary excretion
of homogentisic acid in patients with alkaptonuria
[6,18,19]. As the gene responsible for alkaptonuria has
been identified, replacement therapy with recombinant
enzyme could be a new approach in the treatment of the
disease. Alkaptonuria-associated arthritis is usually
treated with non-steroidal anti-inflammatory drugs. On
the other hand, the prognosis of alkaptonuria is restricted
if there are cardiovascular complications. In our case, we
only saw indications for treatment with ACE inhibitors,
prophylaxis of endocarditis, and annual follow-up. We
opted for conservative treatment because of the enlarge-
ment of the left ventricle and the assumption that aortic
regurgitation would be more severe than mitral regurgita-
tion. In addition, ACE inhibitor treatment is widely rec-
ommended in moderate to severe aortic regurgitation
[20].
Conclusion
Bacterial endocarditis, rheumatic fever and valvular scle-
rosis are the usual causes of valvular heart disease. Our
case report shows that a metabolic disorder like alkapton-
uria can also be a rare cause of valvular disorder. The blu-
ish-black pigmentation of the sclera (indicative of
ochronosis) and the heart murmur (signifying a valvular
problem) were the initial diagnostic clues for this case of
alkaptonuria-induced valvular heart disease. As cardiovas-
cular ochronosis often requires the replacement of
affected heart valves, early diagnosis is important in the
morbidity and mortality of the disease. Conservative ther-
apy using ACE inhibitors, as used in conventional aortic
regurgitation, may slow down the progression of valvular
dysfunction. In summary, although cardiovascular ochro-
nosis is a rare complication in alkaptonuria, patients with
this metabolic disorder should be examined for this con-
dition.
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